• Target：
• Crk II

• Fields：
• >>MAPK signaling pathway;>>ErbB signaling pathway;>>Rap1 signaling pathway;>>Chemokine signaling pathway;>>Focal adhesion;>>Fc gamma R-mediated phagocytosis;>>Neurotrophin signaling pathway;>>Regulation of actin cytoskeleton;>>Insulin signaling pathway;>>Growth hormone synthesis, secretion and action;>>Bacterial invasion of epithelial cells;>>Shigellosis;>>Yersinia infection;>>Human cytomegalovirus infection;>>Human immunodeficiency virus 1 infection;>>Pathways in cancer;>>MicroRNAs in cancer;>>Renal cell carcinoma;>>Chronic myeloid leukemia

• Gene Name：
• CRK

• Protein Name：
• Adapter molecule crk

• Human Gene Id：
• 1398

• Human Swiss Prot No：
• P46108

• Mouse Swiss Prot No：
• Q64010

• Immunogen：
• Purified recombinant fragment of human Crk II expressed in E. Coli.

• Specificity：
• Crk II Monoclonal Antibody detects endogenous levels of Crk II protein.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Monoclonal, Mouse

• Dilution：
• WB 1:500 - 1:2000. IHC 1:200 - 1:1000. IF 1:200 - 1:1000. Flow cytometry: 1:200 - 1:400. ELISA: 1:10000. Not yet tested in other applications.

• Purification：
• Affinity purification

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• CRK;Adapter molecule crk;Proto-oncogene c-Crk;p38

• Molecular Weight(Da)：
• 34kD

• References：
• 1. Seikagaku. 2009 May;81(5):361-76.
  2. Mol Cancer Res. 2009 Sep;7(9):1582-92.

• Background：
• This gene encodes a member of an adapter protein family that binds to several tyrosine-phosphorylated proteins. The product of this gene has several SH2 and SH3 domains (src-homology domains) and is involved in several signaling pathways, recruiting cytoplasmic proteins in the vicinity of tyrosine kinase through SH2-phosphotyrosine interaction. The N-terminal SH2 domain of this protein functions as a positive regulator of transformation whereas the C-terminal SH3 domain functions as a negative regulator of transformation. Two alternative transcripts encoding different isoforms with distinct biological activity have been described. [provided by RefSeq, Jul 2008],

• Function：
• domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation.,domain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4.,PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the down-regulation of the Crk signaling pathway.,PTM:P

• Subcellular Location：
• Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion. .

• Expression：
• Embryonic lung,Epithelium,Eye,Lung,Placenta,

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs